Renal Cell Carcinoma — Trials

Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,621 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 375
Recruiting: 191
Ph III recruiting: 14
Growth YoY: +6.3%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 39.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (276)

clinicaltrialsPublishedShowing 1–50 of 1,621 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04071223	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study	active not recruiting	Phase 2	98	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT07594106	REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma	recruiting	Phase 1 / Phase 2	265	Regeneron PharmaceuticalsINDUSTRY